FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2909397435> ?p ?o ?g. }

• W2909397435 endingPage "2677" @default.
• W2909397435 startingPage "2677" @default.
• W2909397435 abstract "Abstract Background: Patients (pts) with secondary acute myeloid leukemia (s-AML) have poor long-term outcomes following standard induction chemotherapy with 7+3. Last year, a liposomal cytarabine and daunorubicin formulation (CPX-351) was FDA approved for upfront treatment of s-AML based on a pivotal phase 3 trial demonstrating improved overall survival in pts aged 60-75 years old (Lancet J et al; JCO 2018). Although CPX-351 treatment is indicated in all adults with s-AML, it is unclear whether CPX-351 is safe and effective in younger pts < 60 years. We sought to address this unanswered question by retrospective review of clinical experience since FDA approval at 4 large academic centers. Methods: Medical records were retrospectively reviewed at Roswell Park Comprehensive Cancer Center, Moffitt Cancer Center, University of Alabama Comprehensive Cancer Center, and Levine Cancer Institute to identify pts aged 18-59 years old with untreated s-AML defined as antecedent MDS or CMML, prior cytotoxic therapy, or AML with WHO defined myelodysplasia related changes (AML-MRC) treated with CPX-351 as induction therapy. Demographics, disease-specific variables, as well as overall outcomes were collected in accordance with the institutional review board approved protocol. Responses were defined according to the 2003 International Working Group (IWG) criteria. Demographics, baseline clinical characteristics, treatment response, and adverse events were analyzed using descriptive statistics. Overall survival was estimated utilizing Kaplan-Meier (KM) analysis. Results: Twenty-one pts with confirmed s-AML received CPX-351 therapy. Mean age was 54 years (range 42 - 59), 13 were male (62%). The majority (62%, N=13) had AML-MRC, 4 (19%) had treatment-related AML (t-AML) and 4 (19%) had MDS-MRC. Four of 5 pts had received prior hypomethylating therapy. Fourteen pts had a complex karyotype (67%), and 4 patients were found to have a normal karyotype (12%). The most common molecular event was TP53 mutation seen in 9 pts (43%), followed by FLT3-ITD identified in 3 pts (14%). At the time of analysis, response assessments were available for 16 pts. Overall response rate (CR/CRi/PR) was 25% with 1 CR (6.25%, 1/16), 1 CRi (6.25%, 1/16), and 2 PR (13%, 2/16). The remaining pts (12/16, 75%) were non-responders (Table 1). One pt has received an allogenic stem cell transplant. The most common adverse event was infection (81%, 17/21) with 3 clinically significant bleeding events. Thirty-day mortality was 14.3%, with 60-day mortality of 19.1%. Overall survival in all evaluable pts (N=21) was 7.1 months (range 0.5 - 7.4 months) (Figure 1), with mean follow up of 14.8 weeks. Conclusions: This multi-institutional retrospective analysis suggests that CPX-351 results in lower response rates (CR/CRi 12.5%) and shorter overall survival (7.1 mos) than reported in the recently published phase 3 trial data in pts aged 60-75 years old (Table 1). Potential explanations for this discrepancy include short follow up, small sample size, the retrospective design of this study, and the significant proportions of pts with complex karyotype and TP53 mutations. Historically, patients < 65 years old with s-AML have had a reported overall survival of approximately 7 months. Further investigation of this regimen in younger pts with s-AML as compared with 7+3 and other approaches is warranted. Disclosures Thota: Incyte: Speakers Bureau. Baron:Pfizer Pharmaceuticals: Other: Previously served as a consult on the Advisory Boards (May 2017).. Griffiths:Alexion Inc.: Honoraria, Research Funding; Novartis, Inc.: Research Funding; Astex/Otsuka Pharmaceuticals: Honoraria, Research Funding; Pfizer, Inc.: Research Funding; Celgene, Inc: Honoraria, Research Funding. Sweet:Jazz Pharmaceuticals: Honoraria, Speakers Bureau; Bristol Myers Squibb: Honoraria; Incyte: Research Funding; Pfizer: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Speakers Bureau; Agios: Consultancy; Celgene: Speakers Bureau. Wang:Jazz: Speakers Bureau; Jazz: Speakers Bureau; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy; Novartis: Speakers Bureau; Novartis: Speakers Bureau; Amgen: Consultancy; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees." @default.
• W2909397435 created "2019-01-25" @default.
• W2909397435 creator A5030601713 @default.
• W2909397435 creator A5038004259 @default.
• W2909397435 creator A5038660651 @default.
• W2909397435 creator A5046140518 @default.
• W2909397435 creator A5047181107 @default.
• W2909397435 creator A5057933586 @default.
• W2909397435 creator A5060452476 @default.
• W2909397435 creator A5067600974 @default.
• W2909397435 creator A5078571628 @default.
• W2909397435 creator A5078822704 @default.
• W2909397435 date "2018-11-29" @default.
• W2909397435 modified "2023-10-01" @default.
• W2909397435 title "Safety and Efficacy of Liposomal Cytarabine/Daunorubicin (CPX-351) in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia" @default.
• W2909397435 doi "https://doi.org/10.1182/blood-2018-99-113002" @default.
• W2909397435 hasPublicationYear "2018" @default.
• W2909397435 type Work @default.
• W2909397435 sameAs 2909397435 @default.
• W2909397435 citedByCount "1" @default.
• W2909397435 countsByYear W29093974352020 @default.
• W2909397435 crossrefType "journal-article" @default.
• W2909397435 hasAuthorship W2909397435A5030601713 @default.
• W2909397435 hasAuthorship W2909397435A5038004259 @default.
• W2909397435 hasAuthorship W2909397435A5038660651 @default.
• W2909397435 hasAuthorship W2909397435A5046140518 @default.
• W2909397435 hasAuthorship W2909397435A5047181107 @default.
• W2909397435 hasAuthorship W2909397435A5057933586 @default.
• W2909397435 hasAuthorship W2909397435A5060452476 @default.
• W2909397435 hasAuthorship W2909397435A5067600974 @default.
• W2909397435 hasAuthorship W2909397435A5078571628 @default.
• W2909397435 hasAuthorship W2909397435A5078822704 @default.
• W2909397435 hasBestOaLocation W29093974351 @default.
• W2909397435 hasConcept C121608353 @default.
• W2909397435 hasConcept C126322002 @default.
• W2909397435 hasConcept C143998085 @default.
• W2909397435 hasConcept C187212893 @default.
• W2909397435 hasConcept C2777198975 @default.
• W2909397435 hasConcept C2778041864 @default.
• W2909397435 hasConcept C2778336483 @default.
• W2909397435 hasConcept C2778729363 @default.
• W2909397435 hasConcept C71924100 @default.
• W2909397435 hasConceptScore W2909397435C121608353 @default.
• W2909397435 hasConceptScore W2909397435C126322002 @default.
• W2909397435 hasConceptScore W2909397435C143998085 @default.
• W2909397435 hasConceptScore W2909397435C187212893 @default.
• W2909397435 hasConceptScore W2909397435C2777198975 @default.
• W2909397435 hasConceptScore W2909397435C2778041864 @default.
• W2909397435 hasConceptScore W2909397435C2778336483 @default.
• W2909397435 hasConceptScore W2909397435C2778729363 @default.
• W2909397435 hasConceptScore W2909397435C71924100 @default.
• W2909397435 hasIssue "Supplement 1" @default.
• W2909397435 hasLocation W29093974351 @default.
• W2909397435 hasOpenAccess W2909397435 @default.
• W2909397435 hasPrimaryLocation W29093974351 @default.
• W2909397435 hasRelatedWork W1998566700 @default.
• W2909397435 hasRelatedWork W2000123135 @default.
• W2909397435 hasRelatedWork W2522830609 @default.
• W2909397435 hasRelatedWork W2751595153 @default.
• W2909397435 hasRelatedWork W2791064642 @default.
• W2909397435 hasRelatedWork W2889610980 @default.
• W2909397435 hasRelatedWork W2890218132 @default.
• W2909397435 hasRelatedWork W2942757135 @default.
• W2909397435 hasRelatedWork W3045370386 @default.
• W2909397435 hasRelatedWork W2467255834 @default.
• W2909397435 hasVolume "132" @default.
• W2909397435 isParatext "false" @default.
• W2909397435 isRetracted "false" @default.
• W2909397435 magId "2909397435" @default.
• W2909397435 workType "article" @default.